269 related articles for article (PubMed ID: 18927431)
61. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
62. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
63. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
64. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
[TBL] [Abstract][Full Text] [Related]
65. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract][Full Text] [Related]
66. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
Jardin F; Ruminy P; Bastard C; Tilly H
Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
[TBL] [Abstract][Full Text] [Related]
67. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
68. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
[TBL] [Abstract][Full Text] [Related]
69. AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma.
Gu X; Booth CJ; Liu Z; Strout MP
Blood; 2016 Jan; 127(1):102-12. PubMed ID: 26385350
[TBL] [Abstract][Full Text] [Related]
70. Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.
Compton LA; Hiebert SW
Cancer Cell; 2010 Apr; 17(4):315-6. PubMed ID: 20385356
[TBL] [Abstract][Full Text] [Related]
71. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
Cerchietti L; Melnick A
Expert Rev Hematol; 2013 Aug; 6(4):343-5. PubMed ID: 23991920
[No Abstract] [Full Text] [Related]
72. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
[TBL] [Abstract][Full Text] [Related]
73. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
74. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
Ueda C; Akasaka T; Kurata M; Maesako Y; Nishikori M; Ichinohasama R; Imada K; Uchiyama T; Ohno H
Oncogene; 2002 Jan; 21(3):368-76. PubMed ID: 11821949
[TBL] [Abstract][Full Text] [Related]
75. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement.
Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Yamabe H; Edamura S; Dor S; Mori T; Okuma M; Fukuhara S
Br J Haematol; 1996 Jun; 93(4):911-20. PubMed ID: 8703825
[TBL] [Abstract][Full Text] [Related]
76. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells.
Phan RT; Saito M; Basso K; Niu H; Dalla-Favera R
Nat Immunol; 2005 Oct; 6(10):1054-60. PubMed ID: 16142238
[TBL] [Abstract][Full Text] [Related]
77. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
78. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
[TBL] [Abstract][Full Text] [Related]
79. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
Chang CC; Ye BH; Chaganti RS; Dalla-Favera R
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):6947-52. PubMed ID: 8692924
[TBL] [Abstract][Full Text] [Related]
80. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.
Chen YW; Hu XT; Liang AC; Au WY; So CC; Wong ML; Shen L; Tao Q; Chu KM; Kwong YL; Liang RH; Srivastava G
Blood; 2006 Oct; 108(7):2373-83. PubMed ID: 16772602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
